Milwaukee Capital Partners Completes All-Cash Acquisition of MPP Group

Milwaukee Capital Partners LLC (MCP), based in Milwaukee, Wisconsin, has announced its acquisition of MPP Group LLC, located in Mequon, Wisconsin, in an all-cash transaction completed on May 1, 2025. This strategic move marks a significant milestone for both companies as they aim to enhance their operations in the field of pharmaceutical contract research and development.

Joining MCP in this acquisition effort is Concordia University Ventures, spearheaded by Daniel Sem. This partnership underscores the commitment of all parties to foster growth and innovation in scientific and soft manufacturing, particularly in an area as dynamic as the pharmaceutical sector. MPP Group will retain its headquarters in the Mequon Technical Park, a hub known for its rapid growth and excellence in sciences and manufacturing.

Thomas Kintis, the Managing Partner of MCP, will take on the role of Board Chairman and Senior Advisor for MPP Group. Meanwhile, Benjamin Nelson, Ph.D., who is currently the President and Head of Product Development at MPP, will continue to lead the day-to-day operations of the company. This continuity is expected to ensure a seamless transition and maintain the ongoing success of MPP's business interests.

MCP has built a reputation in the private equity investment domain for nurturing emerging technologies and driving innovation through strategic decisions. The acquisition of MPP aligns perfectly with MCP's vision, as it looks to broaden its portfolio and spearhead advancements in the pharmaceutical industry. This transaction also signals a pivotal change in MPP’s strategic direction, enabling them to leverage a considerable cash infusion for enhancing their analytical services and capital investments.

The pharmaceutical landscape is rapidly evolving, and with an increasing focus on bringing pharmaceutical development and manufacturing back to the United States, MPP is strategically positioned to capitalize on these opportunities both domestically and globally. MPP Group specializes in contract analytical services and product research and development, focusing particularly on the development and formulation of injectable drug products. Their services span analytical development, validation, formulation development, container/closure screening, and risk assessments related to elemental impurities.

The location of MPP Group in Southeastern Wisconsin provides excellent access to a pool of talented scientists and engineers, drawn from a network that includes nearby states like Illinois, Indiana, Michigan, Minnesota, and Wisconsin. The strategic positioning is further augmented by proximity to several esteemed Midwestern universities and ease of access to major transportation links, including General Mitchell Field International Airport, just 30 minutes away, and Dane County Regional Airport in Madison, about an hour’s drive.

Founded in 2016 by Michal A. Major, Ph.D., who previously held the position of President at Cambridge Major Laboratories, MPP Group was established to provide an accessible pathway for emerging pharma and biotech companies that often lack testing and development capabilities. MPP takes pride in forging strong partnerships with clients, ensuring a personalized approach in the challenging realm of contract services. The company operates from a 35,000 square foot facility that is FDA inspected and approved, featuring five well-equipped laboratories and over 12,000 square feet available for future sterile manufacturing expansion.

In summary, the acquisition by Milwaukee Capital Partners is poised to facilitate significant growth and innovation within MPP Group, reinforcing their capabilities in the pharmaceutical sector. With a workforce dedicated to advancing drug development and manufacturing in the U.S., both companies are excited about the future and the potential it holds for collaboration and success in the pharmaceutical industry.